{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:18:02Z","timestamp":1774671482080,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Quality Improvement in CML"],"award-info":[{"award-number":["Quality Improvement in CML"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Quality Improvement in CML"],"award-info":[{"award-number":["Quality Improvement in CML"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011566","name":"Sidney Kimmel Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["TIPS Pilot"],"award-info":[{"award-number":["TIPS Pilot"]}],"id":[{"id":"10.13039\/100011566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011566","name":"Sidney Kimmel Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["TIPS Pilot"],"award-info":[{"award-number":["TIPS Pilot"]}],"id":[{"id":"10.13039\/100011566","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients undergoing tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) often face challenges with adherence, despite the efficacy of the treatment. Theory-guided and evidence-informed interventions addressing psychosocial and adherence barriers are critical for promoting adherence. Using a mixed-method approach, the pilot study developed and evaluated the feasibility and potential impact of an intervention \u201ctxt4TKI,\u201d to support medication and symptom management among CML patients undergoing TKI therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Guided by the Necessity and Concerns framework, the study comprised two phases: Phase 1 involved qualitative patient needs assessment interviews informing intervention design. Phase 2 was a single-arm pilot study conducted for 6\u00a0months. The objectives of Phase 2 were to assess the feasibility and acceptability of the <jats:italic>txt4 TKI<\/jats:italic> intervention, examining enrollment and retention rates, intervention utilization, patient satisfaction, and changes in TKI medication adherence, psychosocial and symptom factors, from baseline to the 6-month follow-up. The intervention integrates a smart pill bottle activated with light, chimes to remind medication taking and three proactive text messages per week addressing clinical importance of TKI, symptom, lifestyle, and distress management as well as a biweekly toxicity assessment with tailored management feedback. Adherence was also objectively measured by the smart pill bottle and psychosocial survey was repeatedly assessed at 3- and 6-month.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The intervention, developed iteratively and theoretically through patient-centered inputs (<jats:italic>n<\/jats:italic>\u2009=\u200910) and evidence-based information during Phase 1, integrates knowledge on CML, TKI therapy, self-care symptom management, emotional support, and healthy lifestyle recommendations. In Phase 2, 20 out of 30 eligible patients (67% consent rate), with a mean age of 55.3, 60% females and 65% Non-White participants, were enrolled. Fifty-five percent have been taking their medication for 1\u20133\u00a0years and 50% were taking Dasatinib. A high satisfaction and engagement rate of 90% with an 85% retention rate were observed. While medication self-efficacy significantly improved from baseline to 6\u00a0months, the adherence rate to TKI was slightly decreased over time. Post-intervention interviews indicated that participants found the intervention user-friendly, providing valuable information and emotional support, but adjusting the timing and content of interventions to tailor to different stages of therapy might better support sustained adherence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The <jats:italic>txt4 TKI<\/jats:italic> intervention using interactive text messaging and a smart pill bottle, feasible, and acceptable, demonstrated an increase in medication self-efficacy, an important aspect of medication adherence behaviors. Further research is needed to explore factors that influence the promotion and maintenance of adherence behaviors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09537-z","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T10:00:00Z","timestamp":1748080800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A smart pill bottle and text messaging intervention for promoting medication adherence in patients with chronic myeloid leukemia: a pilot study of txt4 TKI"],"prefix":"10.1007","volume":"33","author":[{"given":"Kuang-Yi","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Palmisiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Keiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Kasner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"9537_CR1","doi-asserted-by":"crossref","unstructured":"Hehlmann, R., M. Lauseker, S. Jung-Munkwitz, A. Leitner, M.C. M\u00fcller, N. Pletsch, . . . L. Balleisen, Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol, 2011. 29(12): p. 1634\u20131642.","DOI":"10.1200\/JCO.2010.32.0598"},{"key":"9537_CR2","unstructured":"Howlader, N., A. Noone, M. Krapcho, J. Garshell, D. Miller, S. Altekruse, . . . Z. Tatalovich, SEER cancer statistics review, 1975\u20132012. Bethesda, MD: National Cancer Institute, 2015. 2015."},{"issue":"3","key":"9537_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2012.082511","volume":"99","author":"L Noens","year":"2014","unstructured":"Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B (2014) Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 99(3):437\u2013447","journal-title":"Haematologica"},{"key":"9537_CR4","doi-asserted-by":"crossref","unstructured":"Efficace, F., M. Baccarani, G. Rosti, F. Cottone, F. Castagnetti, M. Breccia, . . . F. Mandelli, Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer, 2012. 107(6): p. 904\u20139.","DOI":"10.1038\/bjc.2012.348"},{"key":"9537_CR5","doi-asserted-by":"crossref","unstructured":"Noens, L., M.-A. Van Lierde, R. De Bock, G. Verhoef, P. Zach\u00e9e, Z. Berneman, . . . K. MacDonald, Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 2009. 113(22): p. 5401\u20135411.","DOI":"10.1182\/blood-2008-12-196543"},{"key":"9537_CR6","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2147\/PPA.S70712","volume":"8","author":"M Kek\u00e4le","year":"2014","unstructured":"Kek\u00e4le M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M (2014) Chronic myeloid leukemia patients\u2019 adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence 8:1619","journal-title":"Patient Prefer Adherence"},{"key":"9537_CR7","doi-asserted-by":"crossref","unstructured":"Darkow, T., H.J. Henk, S.K. Thomas, W. Feng, J.-F. Baladi, G.A. Goldberg, . . . J. Cortes, Treatment interruptions and non-adherence with imatinib and associated healthcare costs. Pharmacoeconomics, 2007. 25(6): p. 481\u2013496.","DOI":"10.2165\/00019053-200725060-00004"},{"key":"9537_CR8","doi-asserted-by":"crossref","unstructured":"Kapoor, J., N. Agrawal, R. Ahmed, S.K. Sharma, A. Gupta, and D. Bhurani, Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study. Mediterranean journal of hematology and infectious diseases, 2015. 7(1).","DOI":"10.4084\/mjhid.2015.013"},{"key":"9537_CR9","doi-asserted-by":"crossref","unstructured":"Marin, D., A. Bazeos, F.-X. Mahon, L. Eliasson, D. Milojkovic, M. Bua, . . . K. Kozlowski, Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2010. 28(14): p. 2381\u20132388.","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"9537_CR10","doi-asserted-by":"crossref","unstructured":"Deedwania, P.C., M. Gupta, M. Stein, J. Y\u010das, A. Gold, and I.S. Group, Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). The American journal of cardiology, 2007. 99(11): p. 1538-1543","DOI":"10.1016\/j.amjcard.2007.01.028"},{"issue":"1","key":"9537_CR11","first-page":"42","volume":"7","author":"S Bauer","year":"2016","unstructured":"Bauer S, Buchanan S, Ryan I (2016) Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management. J Adv Pract Oncol 7(1):42\u201354","journal-title":"J Adv Pract Oncol"},{"key":"9537_CR12","doi-asserted-by":"crossref","unstructured":"Geissler, J., G. Sharf, F. Bombaci, M. Daban, J. De Jong, T. Gavin, . . . V.S. Hoffmann, Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol, 2017. 143(7): p. 1167\u20131176.","DOI":"10.1007\/s00432-017-2372-z"},{"key":"9537_CR13","doi-asserted-by":"crossref","unstructured":"Tan, B.K., P.C. Bee, S.S. Chua, and L.-C. Chen, Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review. Patient preference and adherence, 2021: p. 2563\u20132575.","DOI":"10.2147\/PPA.S269355"},{"key":"9537_CR14","doi-asserted-by":"crossref","unstructured":"Wen, K.-Y., L.J. Goldstein, R. Smith, and S.M. Miller, Mobile text messaging to improve adjuvant hormone therapy and side effect management among breast cancer patients: A pilot RCT. 2019, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2019.37.15_suppl.e23061"},{"key":"9537_CR15","doi-asserted-by":"crossref","unstructured":"Tan, E.H., A.L.A. Wong, C.C. Tan, P. Wong, S.H. Tan, L.E.Y. Ang, . . . S.C. Lee, Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder. The Breast, 2020. 53: p. 77\u201384.","DOI":"10.1016\/j.breast.2020.06.012"},{"key":"9537_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijmedinf.2019.05.013","volume":"128","author":"A Piau","year":"2019","unstructured":"Piau A, Crissey R, Brechemier D, Balardy L, Nourhashemi F (2019) A smartphone Chatbot application to optimize monitoring of older patients with cancer. Int J Med Informatics 128:18\u201323","journal-title":"Int J Med Informatics"},{"key":"9537_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/1472-6963-13-211","volume":"13","author":"J Chen","year":"2013","unstructured":"Chen J, Ou L, Hollis SJ (2013) A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 13:211","journal-title":"BMC Health Serv Res"},{"key":"9537_CR18","doi-asserted-by":"crossref","unstructured":"Basch, E., A.M. Deal, M.G. Kris, H.I. Scher, C.A. Hudis, P. Sabbatini, . . . D. Schrag, Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. 34(6): p. 557\u2013565.","DOI":"10.1200\/JCO.2015.63.0830"},{"issue":"10","key":"9537_CR19","first-page":"520","volume":"35","author":"SL Beck","year":"2017","unstructured":"Beck SL, Eaton LH, Echeverria C, Mooney KH (2017) SymptomCare@Home: Developing an Integrated Symptom Monitoring and Management System for Outpatients Receiving Chemotherapy. Comput Inform Nurs 35(10):520\u2013529","journal-title":"Comput Inform Nurs"},{"key":"9537_CR20","doi-asserted-by":"crossref","unstructured":"Pereira-Salgado, A., J.A. Westwood, L. Russell, A. Ugalde, B. Ortlepp, J.F. Seymour, . . . P. Schofield, Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment. JMIR Mhealth Uhealth, 2017. 5(12): p. e184.","DOI":"10.2196\/mhealth.8349"},{"key":"9537_CR21","doi-asserted-by":"crossref","unstructured":"Ellsworth, G.B., L.A. Burke, M.T. Wells, S. Mishra, M. Caffrey, D. Liddle, . . . R.M. Gulick, Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. J Acquir Immune Defic Syndr, 2021. 86(1): p. 73\u201380.","DOI":"10.1097\/QAI.0000000000002519"},{"issue":"11","key":"9537_CR22","doi-asserted-by":"publisher","first-page":"e0242210","DOI":"10.1371\/journal.pone.0242210","volume":"15","author":"A Sohn","year":"2020","unstructured":"Sohn A, Speier W, Lan E, Aoki K, Fonarow GC, Ong MK, Arnold CW (2020) Integrating remote monitoring into heart failure patients\u2019 care regimen: A pilot study. PLoS ONE 15(11):e0242210","journal-title":"PLoS ONE"},{"issue":"1","key":"9537_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpsychores.2007.05.004","volume":"64","author":"S Clifford","year":"2008","unstructured":"Clifford S, Barber N, Horne R (2008) Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity\u2013concerns framework. J Psychosom Res 64(1):41\u201346","journal-title":"J Psychosom Res"},{"key":"9537_CR24","doi-asserted-by":"crossref","unstructured":"Cleeland, C.S., T.R. Mendoza, X.S. Wang, C. Chou, M.T. Harle, M. Morrissey, and M.C. Engstrom, Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2000. 89(7): p. 1634\u20131646.","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V"},{"issue":"10","key":"9537_CR25","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1345\/aph.1M174","volume":"43","author":"LS Matza","year":"2009","unstructured":"Matza LS, Park J, Coyne KS, Skinner EP, Malley KG, Wolever RQ (2009) Derivation and validation of the ASK-12 adherence barrier survey. Ann Pharmacother 43(10):1621\u20131630","journal-title":"Ann Pharmacother"},{"issue":"1","key":"9537_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870449908407311","volume":"14","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14(1):1\u201324","journal-title":"Psychol Health"},{"issue":"6","key":"9537_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jpsychores.2005.10.020","volume":"60","author":"E Broadbent","year":"2006","unstructured":"Broadbent E, Petrie KJ, Main J, Weinman J (2006) The brief illness perception questionnaire. J Psychosom Res 60(6):631\u2013637","journal-title":"J Psychosom Res"},{"issue":"1","key":"9537_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1207\/s15327752jpa5201_2","volume":"52","author":"GD Zimet","year":"1988","unstructured":"Zimet GD, Dahlem NW, Zimet SG, Farley GK (1988) The multidimensional scale of perceived social support. J Pers Assess 52(1):30\u201341","journal-title":"J Pers Assess"},{"issue":"12","key":"9537_CR29","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.brat.2003.07.010","volume":"41","author":"M Creamer","year":"2003","unstructured":"Creamer M, Bell R, Failla S (2003) Psychometric properties of the impact of event scale\u2014revised. Behav Res Ther 41(12):1489\u20131496","journal-title":"Behav Res Ther"},{"issue":"3","key":"9537_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0149-7189(82)90074-X","volume":"5","author":"CC Attkisson","year":"1982","unstructured":"Attkisson CC, Zwick R (1982) The Client Satisfaction Questionnaire: Psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann 5(3):233\u2013237","journal-title":"Eval Program Plann"},{"issue":"12","key":"9537_CR31","doi-asserted-by":"publisher","first-page":"e11724","DOI":"10.2196\/11724","volume":"6","author":"XS Ross","year":"2018","unstructured":"Ross XS, Gunn KM, Patterson P, Olver I (2018) Mobile-based oral chemotherapy adherence\u2013enhancing interventions: Scoping review. JMIR Mhealth Uhealth 6(12):e11724","journal-title":"JMIR Mhealth Uhealth"},{"key":"9537_CR32","doi-asserted-by":"crossref","unstructured":"Spoelstra, S.L., A. Sikorskii, A. Majumder, P.S. Burhenn, M. Schueller, and B. Given, Oral Anticancer Agents. Clinical Journal of Oncology Nursing, 2017. 21(2).","DOI":"10.1188\/17.CJON.157-160"},{"key":"9537_CR33","doi-asserted-by":"crossref","unstructured":"Spoelstra, S.L., C.W. Given, A. Sikorskii, C.K. Coursaris, A. Majumder, T. DeKoekkoek, . . . B.A. Given. Feasibility of a text messaging intervention to promote self-management for patients prescribed oral anticancer agents. in Oncol Nurs Forum. 2015.","DOI":"10.1188\/15.ONF.647-657"},{"issue":"10","key":"9537_CR34","doi-asserted-by":"publisher","first-page":"e0186458","DOI":"10.1371\/journal.pone.0186458","volume":"12","author":"L N\u00e1fr\u00e1di","year":"2017","unstructured":"N\u00e1fr\u00e1di L, Nakamoto K, Schulz PJ (2017) Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS ONE 12(10):e0186458","journal-title":"PLoS ONE"},{"issue":"1","key":"9537_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"AM Peterson","year":"2007","unstructured":"Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value in health 10(1):3\u201312","journal-title":"Value in health"},{"key":"9537_CR36","doi-asserted-by":"crossref","unstructured":"Skrabal Ross, X., K.M. Gunn, V. Suppiah, P. Patterson, T. Boyle, C. Carrington, . . . I. Olver, A smartphone program to support adherence to oral chemotherapy in people with cancer: Proof-of-concept trial. Asia Pac J Clin Oncol, 2022. 18(5): p. e378-e387.","DOI":"10.1111\/ajco.13656"},{"issue":"1","key":"9537_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.12892","volume":"166","author":"DM Ross","year":"2014","unstructured":"Ross DM, Hughes TP (2014) How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol 166(1):3\u201311","journal-title":"Br J Haematol"},{"key":"9537_CR38","unstructured":"Greer, J.A., J.M. Jacobs, N. Pensak, L.E. Nisotel, J.N. Fishbein, J.J. MacDonald, . . . J.S. Temel, Randomized Trial of a Smartphone Mobile App to Improve Symptoms and Adherence to Oral Therapy for Cancer. J Natl Compr Canc Netw, 2020. 18(2): p. 133\u2013141."}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09537-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:03:30Z","timestamp":1749492210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09537-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9537"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09537-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with 45 CFR 46. 109 (f)(1), and the protocol was approved by the Ethics Committee of Thomas Jefferson University IRB and Sidney Kimmel Comprehensive Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"498"}}